Medicis Capital

MyoScience Inc., founded in 2005 and based in Redwood City, California, focuses on the development and commercialization of innovative dermatological products. The company leverages advanced technology to create solutions aimed at addressing various skin-related issues. Through its efforts, MyoScience aims to provide effective products that enhance skin health and appearance.

MyoScience Inc., founded in 2005 and based in Redwood City, California, focuses on the development and commercialization of innovative dermatological products. The company leverages advanced technology to create solutions aimed at addressing various skin-related issues. Through its efforts, MyoScience aims to provide effective products that enhance skin health and appearance.

Kiora Pharmaceuticals is a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for eye diseases. The company utilizes its proprietary platform technologies, including a non-invasive iontophoretic drug delivery system known as EyeGate II, which has been developed over a decade in collaboration with the Bascom Palmer Eye Institute at the University of Miami. Kiora Pharmaceuticals is focused on creating effective therapies for various ocular conditions, leveraging its unique delivery system to enhance the administration of medications for chronic diseases affecting the mid and posterior segments of the eye. Among its key products is the EyeGate Ocular Bandage Gel, designed for managing corneal epithelial wounds, and EGP-437, aimed at addressing inflammatory conditions such as ocular inflammation and pain in post-surgical cataract patients. The company has established license agreements with several academic institutions, underscoring its commitment to advancing eye care through innovative pharmaceutical solutions. Kiora Pharmaceuticals is headquartered in Waltham, Massachusetts, and was incorporated in 1998.

Lab21 is a rapidly growing healthcare diagnostics business. The company’s vision is of providing personalised diagnostic testing for disease identification, disease predisposition and personalised medicine to protect people from the health problems of tomorrow. We believe that ‘prevention is better than cure’ and aim to provide information that helps to protect people from their health problems of tomorrow.Lab 21 Clinical Laboratory supports healthcare providers and the pharmaceutical and biotechnology industries with technically advanced testing services from its accredited facilities in Cambridge, UK. The Lab 21 team’s experience and know-how is coupled with a rapidly growing portfolio of molecular and viral diagnostics, plus next generation sequencing, pharmacogenetic and patient profiling tests, which all use cutting-edge technology. This unique combination adds value to pharmaceutical, diagnostic and biotech partners – and directly to clinicians or healthcare providers as they treat and monitor their patients.As we move towards truly personalised healthcare, the Lab 21 team contributes today – delivering high-quality information on drugs and patients that provides real clinical insight.

Kiora Pharmaceuticals is a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for eye diseases. The company utilizes its proprietary platform technologies, including a non-invasive iontophoretic drug delivery system known as EyeGate II, which has been developed over a decade in collaboration with the Bascom Palmer Eye Institute at the University of Miami. Kiora Pharmaceuticals is focused on creating effective therapies for various ocular conditions, leveraging its unique delivery system to enhance the administration of medications for chronic diseases affecting the mid and posterior segments of the eye. Among its key products is the EyeGate Ocular Bandage Gel, designed for managing corneal epithelial wounds, and EGP-437, aimed at addressing inflammatory conditions such as ocular inflammation and pain in post-surgical cataract patients. The company has established license agreements with several academic institutions, underscoring its commitment to advancing eye care through innovative pharmaceutical solutions. Kiora Pharmaceuticals is headquartered in Waltham, Massachusetts, and was incorporated in 1998.

Hybrigenics Pharma is a bio-pharmaceutical company with a focus on research and development of new targets and therapies against cancer.Hybrigenics Pharma has stopped the development of inecalcitol, a vitamin D receptor agonist.Hybrigenics Pharma's research program investigates the action of enzymes called Deubiquitinating Enzymes (DUBs) in the recycling of onco-proteins and the potential activity of proprietary patented DUB inhibitors against various cancer indications.